Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colectomy | 2 | 2009 | 288 | 0.370 |
Why?
|
| Hospitals, Veterans | 2 | 2009 | 397 | 0.360 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2009 | 275 | 0.320 |
Why?
|
| Colorectal Neoplasms | 8 | 2011 | 3578 | 0.320 |
Why?
|
| Rectal Neoplasms | 3 | 2010 | 1202 | 0.290 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2009 | 605 | 0.260 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 585 | 0.240 |
Why?
|
| Delivery of Health Care | 1 | 2009 | 860 | 0.200 |
Why?
|
| Analgesia, Epidural | 1 | 2021 | 102 | 0.180 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2021 | 1724 | 0.180 |
Why?
|
| Laparoscopy | 3 | 2016 | 1225 | 0.170 |
Why?
|
| Veterans | 2 | 2010 | 1641 | 0.160 |
Why?
|
| Blood Transfusion | 1 | 2021 | 583 | 0.160 |
Why?
|
| Pancreatectomy | 1 | 2021 | 652 | 0.150 |
Why?
|
| Adenocarcinoma | 4 | 2021 | 7789 | 0.130 |
Why?
|
| Obesity | 4 | 2010 | 2884 | 0.120 |
Why?
|
| Waist Circumference | 2 | 2010 | 92 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 2 | 2021 | 5061 | 0.110 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2010 | 500 | 0.110 |
Why?
|
| Postoperative Complications | 3 | 2010 | 5542 | 0.100 |
Why?
|
| Hepatectomy | 1 | 2016 | 1011 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 4975 | 0.090 |
Why?
|
| Surgical Wound Infection | 2 | 2010 | 450 | 0.090 |
Why?
|
| Thrombospondin 1 | 1 | 2009 | 55 | 0.090 |
Why?
|
| Dissection | 1 | 2009 | 156 | 0.090 |
Why?
|
| Length of Stay | 3 | 2010 | 1900 | 0.080 |
Why?
|
| Peripheral Nerves | 1 | 2009 | 159 | 0.080 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2009 | 72 | 0.080 |
Why?
|
| Neurogenesis | 1 | 2011 | 238 | 0.080 |
Why?
|
| Patient Selection | 1 | 2016 | 2055 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 261 | 0.080 |
Why?
|
| General Surgery | 1 | 2011 | 326 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2010 | 703 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 280 | 0.070 |
Why?
|
| Aged | 12 | 2021 | 70117 | 0.070 |
Why?
|
| Cancer Care Facilities | 1 | 2011 | 884 | 0.070 |
Why?
|
| Elastin | 1 | 2005 | 49 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2011 | 795 | 0.070 |
Why?
|
| Colonoscopy | 1 | 2009 | 518 | 0.060 |
Why?
|
| Male | 15 | 2021 | 123000 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2005 | 143 | 0.060 |
Why?
|
| Middle Aged | 11 | 2021 | 86204 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2009 | 1271 | 0.060 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2005 | 315 | 0.060 |
Why?
|
| Female | 14 | 2021 | 141928 | 0.060 |
Why?
|
| Aortic Aneurysm | 1 | 2005 | 230 | 0.050 |
Why?
|
| United States | 2 | 2009 | 15433 | 0.050 |
Why?
|
| Disease-Free Survival | 5 | 2011 | 10001 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2009 | 1270 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2009 | 2022 | 0.050 |
Why?
|
| Humans | 18 | 2021 | 261506 | 0.050 |
Why?
|
| Prognosis | 5 | 2021 | 21713 | 0.050 |
Why?
|
| Abdominal Muscles | 1 | 2021 | 68 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 12873 | 0.050 |
Why?
|
| Survival Rate | 3 | 2021 | 12221 | 0.050 |
Why?
|
| Aortic Valve | 1 | 2005 | 581 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2021 | 37905 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 2927 | 0.040 |
Why?
|
| Comorbidity | 3 | 2010 | 2352 | 0.040 |
Why?
|
| Sarcoma | 1 | 2009 | 1725 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 15862 | 0.040 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2005 | 595 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2010 | 2203 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2021 | 953 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 475 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2020 | 690 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2021 | 610 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2020 | 1450 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 8865 | 0.030 |
Why?
|
| Quality of Life | 1 | 2009 | 4532 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 7551 | 0.030 |
Why?
|
| Risk Factors | 4 | 2011 | 17523 | 0.030 |
Why?
|
| Anesthesia | 1 | 2016 | 296 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 4892 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2009 | 3981 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 1371 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6207 | 0.020 |
Why?
|
| Gelatinases | 1 | 2009 | 52 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2009 | 43 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2010 | 129 | 0.020 |
Why?
|
| Intra-Abdominal Fat | 1 | 2010 | 95 | 0.020 |
Why?
|
| CD36 Antigens | 1 | 2009 | 53 | 0.020 |
Why?
|
| Personnel Selection | 1 | 2011 | 87 | 0.020 |
Why?
|
| Subcutaneous Fat | 1 | 2010 | 92 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 760 | 0.020 |
Why?
|
| Texas | 2 | 2010 | 6311 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 589 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2011 | 29902 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 14889 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2010 | 661 | 0.020 |
Why?
|
| Reoperation | 1 | 2010 | 1382 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2005 | 19 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2005 | 66 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 2231 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2009 | 984 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2010 | 2218 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2009 | 2450 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 4298 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2009 | 5395 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2009 | 1824 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 4844 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 1489 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 1054 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 3890 | 0.010 |
Why?
|
| Hypertension | 1 | 2010 | 1503 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 2005 | 546 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 6009 | 0.010 |
Why?
|
| Disease Progression | 1 | 2011 | 6682 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2010 | 32848 | 0.010 |
Why?
|
| Adult | 3 | 2011 | 77950 | 0.010 |
Why?
|
| Gene Expression | 1 | 2005 | 3570 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 7222 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 14551 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 6150 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 13658 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 7548 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 10035 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 5767 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 11965 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 14289 | 0.000 |
Why?
|
| Animals | 1 | 2009 | 59536 | 0.000 |
Why?
|